anti-Podocalyxin-Like (PODXL) Antikörper

Human Podocalyxin-Like (PODXL) Interaktionspartner

1. Heterozygous PODXL nonsense mutations may have a role in the development of autosomal dominant focal segmental glomerulosclerosis.

2. At 11-13 weeks of gestation, serum podocalyxin was significantly elevated in women who subsequently developed preeclampsia.

3. Urine markers of podocyte dysfunction: a review of podocalyxin and nephrin in selected glomerular diseases.

4. The aim of the present study was to assess PODXL expression in tumors from patients treated with neoadjuvant +/- adjuvant (i.e. preoperative with or without postoperative) chemotherapy, with regard to histopathologic response, time to recurrence (TTR) and overall survival.

5. KLF4/PODXL signaling pathway assumes an irreplaceable role in tumorigenesis, invasion and metastasis of human gastric cancer

6. An increased urinary level of podocalyxin may be a marker of both active nephron formation and podocyte injury sustained at birth.

7. Data suggest that targeting the podocalyxin-like protein (PODXL)/RUN and FYVE domain containing 1 (RUFY1) complex might improve cancer therapy.

8. s-Podxl is independently associated with carotid IMT and might be used as a novel biomarker for cardiovascular disease.

9. Results show high podocalyxin expression in prostate cancer and can be used as a tumor marker for disease progression and patients stratification.

10. Summary of the structural features of podocalyxin glycoforms from embryonic and induced pluripotent stem cells (review).

11. This set of symptoms strikingly mimics previously reported mouse Podxl(-/-) embryos, emphasizing the essential function of PODXL in mammalian kidney development and highlighting this patient as a human PODXL-null model.

12. These results indicate that PcMab-47 is useful in detecting podocalyxin of oral cancers for immunohistochemical analysis

13. expression of PODXL associates with TAZ downstream gene expression. Suppression of PODXL induces phosphorylation of LATS1 and TAZ, and is accompanied with a decrease in TAZ protein expression. We speculate that changes in actin cytoskeleton may participate in PODXL-mediated TAZ signaling.

14. Results show that PODXL performs as a tumor promoter in gastric tumor cells (GC). PODXL is a target gene of miR-509-3-5P; the ectopic expression of miR-509-3-5P in GC cell lines inhibits the colony, motility and invasion abilities via negatively targeting PODXL.

15. Podocalyxin as a major pluripotent marker and novel keratan sulfate proteoglycan in human embryonic and induced pluripotent stem cells.

16. A novel frameshift mutation in PODXL seems to be the likely cause of ARJP in this family.

17. These findings suggest a potential functional link in colorectal cancer between PODXL, EGFR and BRAF.

18. PODXL enhances motility and invasiveness through an increase in gelsolin-actin interactions in cell protrusions.

19. Results identify an anti-metastatic miRNA, miR-5100, that decreases the metastatic ability of pancreatic cancer partially by suppressing expression of PODXL.

20. Results indicate that urinary podocalyxin is not only an early marker but also a treatment target for diabetic nephropathy (DN).

Mouse (Murine) Podocalyxin-Like (PODXL) Interaktionspartner

1. Podocalyxin-like protein 1 is a relevant marker for human c-kit(pos) cardiac stem cells.(

2. Podxl-KO led to heightened G-CSF activation of Rap1a(GTP), and Rap1a(GTP) inhibition attenuated Podxl-KO neutrophil migration. Studies have revealed novel roles for Podxl as an important modulator of neutrophil and monocyte formation and of Rap1a activation during stress hematopoiesis.

3. Podxl-overexpression in neural stem/progenitor cells leads to an up-regulation of Annexin A2.

4. when endogenous podocalyxin was removed from highly metastatic 4T1 mammary tumor cells there was a decrease in collective invasion . Podocalyxin is a tumor cell-intrinsic regulator of experimental collective tumor cell invasion and tumor budding.

5. Podocalyxin has a role in glioblastoma multiforme cell invasion and proliferation via beta-catenin signaling

6. Loss of podocalyxin from the lung vasculature results in changes to the lung structure and function including increased lung volume when inflated under constant pressure (25 cm H2O) and changes to the matrix composition.

7. CTGF is an important mediator of high glucose-induced podocyte damage and decreases the protein level of podocalyxin by the ERK1/2 pathway.

8. platelet Podxl is involved in the control of hemostasis acting as a platelet co-stimulator, likely due to its pro-adhesive properties

9. Full-length recombinant murine podocalyxin recruits NHERF-1 to the apical domain. Ectopic expression in human & canine epithelial cells leads to microvilli formation on an apical domain extending laterally to the junctional complexes.

10. Podocalyxin plays multiple roles in neural development

11. PODXL may act as a costimulator of agonists in the activation of platelets and formation of a stable thrombus.

12. Data show that in podocalyxin-deficient mice, the thickness of the main carotid artery is significantly increased, and there is an increased number of choroidal capillaries lining the ventricular spaces.

13. Podocalyxin mRNA was widely expressed at least from E14, the first age we studied, and expression remained high until adulthood

14. In mice expressing an Erythropoietin receptor allele, compromised erythropoietin-induced podocalyxin expression correlated with enucleated red cells in bone marrow.

15. PODXL(hi)/CD49f(hi) MSCs were less prone to produce lethal pulmonary emboli

16. Podocalyxin selectively marks erythroid-committed progenitors during anemic stress but is dispensable for efficient recovery.

17. Podocalyxin is required for normal kidney function